CYP2C19 Polymorphism in Ischemic Heart Disease Patients Taking Clopidogrel After Percutaneous Coronary Intervention
Ahmed Shawky1, Hussein Sabit2, Mahmoud Nazih3,4
1Department of Cardiology, College of Medicine, Helwan University, Cairo, Egypt.
Insights
Genetic variations in CYP2C19 affect clopidogrel metabolism, increasing cardiovascular event risk. Understanding these variations can personalize antiplatelet therapy for ischemic heart disease patients post-PCI.
Area of Science:
- Pharmacogenetics
- Cardiovascular Medicine
- Genetics
Background:
- Cardiovascular diseases (CVDs) are a leading global cause of mortality.
- Allelic variations in the CYP2C19 gene impair clopidogrel metabolism, increasing the risk of major adverse cardiovascular events (MACE).
- This study focuses on ischemic heart disease patients undergoing percutaneous cardiac intervention (PCI) and treated with clopidogrel.
Purpose of the Study:
- To investigate the correlation between CYP2C19 genetic variations and MACE in patients treated with clopidogrel after PCI.
- To identify demographic and clinical factors associated with abnormal clopidogrel metabolism.
Main Methods:
- Genotyping of CYP2C19 variations using TaqMan chemistry-based qPCR.
- One-year follow-up of 102 ischemic heart disease patients to monitor MACE.
- Analysis of demographic data and clinical factors (diabetes, hypertension, smoking) in relation to CYP2C19 genotype.
Main Results:
- 51% of patients were identified as abnormal clopidogrel metabolizers based on CYP2C19 genotype.
- Age, residency, diabetes, hypertension, and cigarette smoking were significantly associated with abnormal clopidogrel metabolism.
- Inter-ethnic variations in clopidogrel metabolism were observed, linked to CYP2C19 allelic distribution.
Conclusions:
- CYP2C19 genotype significantly influences clopidogrel metabolism and MACE risk in patients undergoing PCI.
- Clinical factors like diabetes and hypertension exacerbate the impact of genetic variations on drug metabolism.
- Findings highlight the importance of pharmacogenetic profiling for personalized antiplatelet therapy in CVD patients.
Background:
Cardiovascular diseases (CVDs) are considered a leading cause of death worldwide. Allelic variation in the CYP2C19 gene leads to a dysfunctional enzyme, and patients with this loss-of-function allele will have an impaired clopidogrel metabolism, which eventually results in major adverse cardiovascular events (MACE). Ischemic heart disease patients (n = 102) who underwent percutaneous cardiac intervention (PCI) followed by clopidogrel were enrolled in the present study.
Methods:
The genetic variations in the CYP2C19 gene were identified using the TaqMan chemistry-based qPCR technique. Patients were followed up for 1 year to monitor MACE, and the correlations between the allelic variations in CYP2C19 and MACE were recorded.
Results:
During the follow-up, we reported 64 patients without MACE (29 with unstable angina (UA), 8 with myocadiac infarction (MI), 1 patient with non-STEMI, and 1 patient with ischemic dilated cardiomyopathy (IDC)). Genotyping of CYP2C19 in the patients who underwent PCI and were treated with clopidogrel revealed that 50 patients (49%) were normal metabolizers for clopidogrel with genotype CYP2C19*1/*1 and 52 patients (51%) were abnormal metabolizers, with genotypes CYP2C19*1/*2 (n = 15), CYP2C19*1/*3 (n = 1), CYP2C19*1/*17 (n = 35), and CYP2C19*2/*17 (n = 1). Demographic data indicated that age and residency were significantly associated with abnormal clopidogrel metabolism. Moreover, diabetes, hypertension, and cigarette smoking were significantly associated with the abnormal metabolism of clopidogrel. These data shed light on the inter-ethnic variation in metabolizing clopidogrel based on the CYP2C19 allelic distribution.
Conclusion:
This study, along with other studies that address genotype variation of clopidogrel-metabolizing enzymes, might pave the way for further understanding of the pharmacogenetic background of CVD-related drugs.
Related Concept Videos
01:27Coronary Artery Disease V: Interprofessional Care
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Peripheral Artery Disease III: Interprofessional Care
01:26Coronary Artery Disease IV: Preventive Measures
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...